- Home
- FHI vs KNSA Comparison
FHI vs KNSA Comparison
Compare FHI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHI | KNSA |
|---|---|---|
| Founded | 1955 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FHI | KNSA |
|---|---|---|
| Price | $56.23 | $48.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $54.20 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 705.0K | 501.4K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | 58.82 | ★ 225.00 |
| EPS | ★ 1.27 | 0.27 |
| Revenue | ★ $1,102,924,000.00 | $677,564,000.00 |
| Revenue This Year | $9.90 | $37.48 |
| Revenue Next Year | $4.35 | $17.87 |
| P/E Ratio | ★ $43.54 | $188.52 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $41.55 | $26.27 |
| 52 Week High | $59.05 | $59.87 |
Technical Indicators
Market Signals| Indicator | FHI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 36.64 |
| Support Level | $51.62 | $40.67 |
| Resistance Level | $57.35 | $49.57 |
| Average True Range (ATR) | 1.45 | 2.02 |
| MACD | 0.21 | -1.15 |
| Stochastic Oscillator | 76.98 | 3.18 |
Price Performance
Historical ComparisonAbout FHI Federated Hermes Inc.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $902.6 billion in managed assets at the end of 2025, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (76%) funds. The firm's cash management operations are expected to generate around 55% of Federated's revenue this year, compared with 27%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (68% of AUM), institutional investors (25%), and international clients (7%).
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.